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doi:10.1016/j.jmii.2011.04.004Background: Cytomegalovirus (CMV) is a pathogen and can cause life-threatening infection in
the patients with malignancies. This study was conducted to investigate the risk factors and
outcomes of CMV viremia in patients with malignancies.
Methods: Data were collected with retrospective analysis from adults suffering from CMV
viremia with underlying malignancies. A total of 107 patients were enrolled in a tertiary
medical center in northern Taiwan from March 2008 to December 2009.
Results: Among the 107 patients who suffered with CMV viremia with an overall mortality rate
of 56.1% (60/107), 75 patients (70.1%) had solid organ malignancies and 32 (29.9%) had hema-
tological malignancies. Mechanical ventilation (pZ 0.048), leukocytosis (pZ 0.004), and lack
of appropriate early treatment (pZ 0.011) were independent predisposing factors associated
with higher mortality rate.
Conclusions: CMV viremia predicts high mortality rate in cancer patients, especially in those
with mechanical ventilation, leukocytosis, and lack of appropriate early treatment. Appro-
priate early antiviral therapy is recommended to improve outcomes.
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Cytomegalovirus (CMV) is an important cause of bothmorbidity
and mortality in immunocompromised hosts, including cancer
patients.1e3 Patients with CMV infection have a wide variety of
clinical manifestations, including fever, encephalitis, pneumo-
nitis, retinitis, hepatitis, enterocolitis, nephritis, and dissemi-
nated disease.4e7 The exact mechanism of the reactivation of
CMV is not well established; however, disturbance of the host’s
immune defenses plays an important role.8e10 Immune
impairment in thepatientswithmalignancieswas considered to
be a risk factor for CMV disease.9,10 The term “CMV infection”
indicates latent and asymptomatic form of infection,9 whereas
the “CMV disease” means the symptomatic end-organ involve-
ment.9 The incidence of CMV infection in patients with malig-
nancies varies in different studies.11e13
Several tests, such as viral culture, antigenemia assay,
and polymerase chain reaction (PCR) were used for the
diagnosis of CMV infection.9,10,14,15 Of all the laboratory
tests, PCR is the most sensitive and rapid method for early
diagnosis.14,15 Both “prophylaxis” and the ”pre-emptive
treatment” have been proposed as the therapeutic strate-
gies.9,16 The “pre-emptive therapy” was defined as antiviral
therapy given for the laboratory evidence of viral replica-
tion (detected by viral culture, antigenemia, and PCR). In
Taiwan, there are limited clinical data of the patients
suffering with CMV infection accompanied with malignan-
cies. Thus, we conducted this study to elucidate the risk
factors and outcomes in these patients.
Methods
Study design
The clinical and microbiological data we retrospectively
evaluated were the cases of CMV viremia in Tri-Service
General Hospital from March 2008 to December 2009. Only
patients with solid organ malignancies or hematological
malignancies were enrolled. Patients either infected with
human immunodeficiency virus or who received solid organ
or bone marrow transplantation were excluded.
Patient enrollment and data collection
Information of patients enrolled in the study was obtained
from the medical records, including demographic charac-
teristics, predisposing factors, comorbid conditions, labo-
ratory data, and treatment outcomes.
PCR
Weused two sets of primers, one specific for CMVand the other
specific for human DNA. The CMV primers were directed at
a conserved regionof theDNApolymerase geneof strainAD169.
Thenucleotide sequencewere50-GCTGACGCGTTTGGTCATC-
30 (CPOL-F720) for the forward primer and 50-ACGATTCACGGA
GCA CCA G-30 (CPOL-R780) for the reverse primer. The internal
probe (CPOL-741FAM), 50-TCG GCG GAT CAC CAC GTT CG, was
labeled at the 50 end with the fluorescent dye 6-carboxy-
fluorescein and on the 30 end with the quencher dye 6-carboxytetramethylrhodamine (TETRA). The real-time, quan-
titative CMV PCR assay did not amplify laboratory strains of any
of the other seven human herpes viruses.14
Definitions
We used the real-time PCR assay for the diagnosis of the
infection. Positive result of CMV-specific real-time PCR assay
in serum was defined as CMV viremia. Exposure to chemo-
therapy was defined as receiving chemotherapeutic agents
within 1 week before the diagnosis of CMV viremia. Coin-
fection was defined as the presence of other microorganisms
identified from the blood simultaneously with CMV. Labora-
tory data obtained within 7 days before the diagnosis of CMV
viremia were analyzed. Leukocytosis was defined as a leuko-
cyte count of more than 10,000 cells/mL and leukopenia was
defined as a leukocyte count of less than 4,000 cells/mL.
Neutropenia was defined as an absolute neutrophil count less
than 500 cells/mL or less than 1,000 cells/mL with a predicted
nadir of less than500cells/mL. Lymphopeniawasdefinedasan
absolute lymphocyte count of less than 1,000 cells/mL. Anti-
viral therapy started within 3 days of the diagnosis and lasted
at least 3 days was considered to be appropriate early treat-
ment. The overall mortality was defined as fatality within 30
days of the emergence of viremia.
Statistical analysis
All statistical analyses were performed by using the
Statistical Package for the Social Sciences (SPSS) for
windows (Version 17.0; SPSS, Chicago, IL, USA). Continuous
variables were analyzed by unpaired Student t test.
Comparisons between categorical variables were calcu-
lated using the Pearson c2 test or Fisher’s exact tests.
Univariate analysis was performed to demonstrate the
association between potential risk factors and overall
mortality associated with CMV viremia. Multiple logistic
regression analysis was conducted to determine the inde-
pendent risk factor for mortality associated with CMV
viremia. Odds ratios and 95% confidential intervals were
calculated to evaluate the strength of any association and
estimate the effect in the outcome analysis. A p value less
than 0.05 was considered to be statistically significant.
Results
During the 22-month study period, 107 patients with posi-
tive result of CMV-specific PCR were enrolled. The demo-
graphics, predisposing factors, comorbid conditions, and
the laboratory data are listed in Table 1. The mean
standard deviation age of the patients was 65.6 15.8
years (range 26e100 years) and the male to female ratio
was 1.89 (70 men and 37 women). Sixty-two patients
(66.34%) were exposed to chemotherapeutic agents within
1 week before the diagnosis of viremia. Twenty-seven
patients (28.89%) had received steroids before the
viremia. Diabetes mellitus was the most common comor-
bidity (nZ 33; 30.8%) followed by congestive heart failure
(nZ 17; 15.9%) and liver cirrhosis (nZ 18; 9.0%). Thirty
patients (28%) received appropriate early treatment,
whereas the other 77 patients (72%) did not have adequate
Table 1 Demographics, predisposing factors, and treatment outcomes for cytomegalovirus viremic patients with underlying
solid organ malignancy and hematological malignancy
Variables All patients
(nZ 107)
Solid organ
malignancy
group (nZ 75)
Hematological
malignancy
group (nZ 32)
pa
Age (yr) 65.6 15.8 63 16.6 71.8 11.9 0.003
Sex
Men 70 (65.4) 49 (65.3) 21 (65.6) 0.977
Women 37 (34.6) 26 (34.7) 11 (34.4)
Comorbid conditions
Congestive heart failure 17 (15.9) 13 (17.3) 4 (12.5) 0.531
Liver cirrhosis 4 (3.7) 4 (5.3) 0 (0) 0.183
Chronic obstructive lung disease 5 (4.7) 3 (4) 2 (6.3) 0.614
Diabetes 33 (30.8) 21 (28) 12 (37.5) 0.330
Rheumatological disease 4 (3.7) 3 (4) 1 (3.1) 0.827
Renal failure 5 (4.7) 4 (5.3) 1 (3.1) 0.620
Predisposing factors
Receipt of chemotherapy 62 (57.9) 45 (60) 17 (53.1) 0.510
Use of corticosteroids 27 (25.2) 16 (21.3) 11 (34.4) 0.155
Mechanical ventilation 35 (32.7) 27 (36) 8 (25) 0.267
Coinfection 21 (19.6) 12 (16) 9 (28.1) 0.148
Presentations
Leukocytosis 35 (32.7) 30 (40) 5 (15.6) 0.014
Neutropenia 21 (19.6) 8 (10.7) 13 (40.6) <0.001
Lymphopenia 90 (84.1) 63 (84) 24 (84.4) 0.961
Treatment and outcomes
Lack of early appropriate treatment 77 (72) 56 (74.7) 21 (65.6) 0.340
Mortality 60 (56.1) 46 (61.3) 14 (43.8)a 0.093
a Comparison between patients with solid organ and hematological malignancy by univariate analysis.
Data are presented as n (%) or mean SD.
SDZ standard deviation.
444 Y.-C. Wang et al.early treatment. Ten patients did not receive any treat-
ment throughout the course of the infection. Seven of them
died because of mortality before the diagnosis. Intravenous
ganciclovir was the only antiviral agent used in this study.
Sixty patients died in this study, accounting for an overall
mortality rate of 56.1%.
Comparisonof thedemographics, comorbidconditions, and
clinicaloutcomesofpatientswithsolidorganmalignanciesand
hematological malignancies are summarized in Table 1.
Seventy-fivepatients (70.1%) had solid organmalignancies and
the 32 patients (29.9%) had hematological malignancies. The
mean age of patients with solid organ malignancies was
younger than those with hematological malignancies (63.0 vs.
71.8; pZ 0.03). No statistical difference was noted in
comorbid conditionsbetweenbothgroups. Themortality rates
in patients with solid organ malignancies were higher than
those with hematological malignancies (61.3% vs. 43.8%)
without statistical significance specifically (pZ 0.093).
The underlying malignancies of the 107 patients are
shown in Table 2. In solid organ malignancies group, lung
cancer was the most common (31/75; 41.3%), followed by
colorectal cancer (7/75; 9.3%), breast cancer (6/75; 8%),
and oral cavity cancer (6/75; 8%). One patient had
synchronous malignancies of lung cancer and breast cancer.
Only three kinds of hematological malignancies were foundin the hematological group, including lymphoma, multiple
myeloma, and acute lymphoblastic leukemia. Lymphoma
was the most common hematological malignancy in this
study accounting for more than one-half of the malignan-
cies (26/32; 81.3%).
Twenty-one patients had coinfection with either
bacteremia or fungemia (Table 3). The overall mortality
rate in patients with coinfection was 52.4% (nZ 11)
without statistical significance. In patients who had coin-
fection with other microbes, Candida albicans fungemia (6/
21; 28.6%) and Klebsiella pneumoniae (5/21; 23.8%) were
the most common, followed by Pseudomonas aeruginosa
and methicillin-resistant Staphylococcus aureus (3/21;
14.3%). One patient having coinfection of Methicillin-
resistant S aureus bacteremia and candidemia died
despite the treatment. The overall mortality associated
with CMV viremia was 56.1% (60/107).
Univariant analysis showed that without exposure to
chemotherapy before the viremia (pZ 0.024), mechanical
ventilation (pZ 0.010), leukocytosis (pZ 0.003), hypo-
albuminemia (< 3 g/dl) (pZ 0.002), and lack of appro-
priate early treatment (pZ 0.039) were associated with
higher mortality (Table 4). In the multivariate analysis,
mechanical ventilation (pZ 0.048; 95% confidence inter-
valZ 1.012e10.489; odds ratioZ 3.259), leukocytosis
Table 2 Underlying malignancies in 107 patients with
cytomegalovirus infection (nZ 107)
Underlying malignancy n
Solid organ malignancy 75
Lung cancer 31
Colorectal cancer 7
Breast cancer 6
Oral cavity cancer 6
Hepatocellular carcinoma 4
Bladder cancer 2
Cervix cancer 2
Cholangiocarcinoma 2
Esophageal cancer 2
Nasopharyngeal carcinoma 2
Prostate cancer 2
Renal cell carcinoma 2
Duodenal cancer 1
Gastric cancer 1
Glioblastoma multiforme 1
Melanoma 1
Pancreas cancer 1
Plantar cancer 1
Synchronous malignancy 1
Hematological malignancy 32
Lymphoma 26
Multiple myeloma 5
Leukemia 1
Total 107
Cytomegalovirus viremia in cancer patients 445(pZ 0.004; 95% confidence intervalZ 1.831e25.663; odds
ratioZ 6.885), and the lack of appropriate antiviral
therapy (pZ 0.011; 95% confidence inter-
valZ 1.451e18.095; odds ratioZ 5.124) were independent
risk factors for mortality associated with CMV viremia in
cancer patients.
Discussion
CMV, belonging to herpes virus, is an important pathogen to
human. After initiation, the CMV establishes lifelong orTable 3 Concurrent pathogens in 21 patients with coin-
fection with other microorganisms (nZ 22)
Pathogen Number of
isolates
Bacteria 16
Klebsiella pneumoniae 5
Pseudomonas aeruginosa 3
Methicillin-resistant
Staphylococcus aureusa
3
Escherichia coli 2
Enterobacter cloacae 2
Serratia marcescens 1
Fungus 6
Candida albicansa 6
Total 22
a One patient had co-infection with Methicillin-resistant
Staphylococcus aureus and Candida albicans.persistent infection in the host.15,16 It may reactivate and
produce consistently infectious virions that exist in the saliva,
urine, and other body fluids.15,16 Reactivation of CMV infec-
tion has been observed in patients with liver cirrhosis, sepsis,
following trauma, critically ill condition, and impaired
immune response, such as post-transplantation of organs and
human immunodeficiency virus infection.8,10,16e19 Patients
with solid organ or hematological malignancies were thought
to have impaired immunities and high risk of opportunistic
infection, including the CMV infection.1e3,12,20e22 In the
absence of effective antiviral prophylaxis, the incidence of
CMV infection ranges from 5% to 75% among patients with
hematological malignancies.21 An early prospective surveil-
lance study reported the incidence of CMV infection in
patients with acute leukemia that ranged from 32% to
58%.3,20e24 However, the true incidence and consequences of
viral infections for cancer patients were poorly identified.
Diagnostic tests for CMV infections include viral culture,
antigen detection, PCR, and even serological and histo-
pathological methods.10,11,14,15 Of all, the real-time PCR is
the most sensitive and rapid assay for the diagnosis of the
infection.9,10,14,15 The high sensitivity and negative predict
value make it an important method for the early diagnosis of
the infection.9,10,14,15 Despite the low positive predict value
for recognizing clinically significant infection, PCR remains
crucial in the early diagnosis of the disease.
Ganciclovir and foscavir are the drugs of choice in the
treatment for CMV infection. Three major therapeutic
strategies are used for managing CMV infection, namely
prophylaxis, pre-emptive treatment, and treatment for
established diseases. Although prophylaxis is used for early
prevention of CMV infection, the treatment of established
disease is applied in patients with well-identified end-organ
diseases. The pre-emptive therapy was first documented in
the 1990s as a means of reducing of CMV disease.9,10,25 This
strategy has the advantage for early treatment for pre-
venting the progression to end-organ diseases, reducing the
exposure to antiviral toxicity, and maximizing the cost-
benefit ratio.9,25e27
No previous study was conducted for analyzing the
mortality rate of CMV viremia in solid organ malignancies.
The overall mortality rate in this study was 56.1% (60/107).
Worse outcome was found in patients with solid organ
malignancies (61.3%) than those with hematological malig-
nancies. The mortality rate in patients with hematological
malignancies was 43.8% (14/32), which was compatible with
previous studies with the mortality rate ranging from 30% to
57%.4 In the multivariate analysis, leukocytosis (pZ 0.008),
mechanical ventilation (pZ 0.011), and the lack of appro-
priate antiviral therapy (pZ 0.100) were independent risk
factors for mortality associated with CMV viremia. The
results of our study indicated that CMV viremia in cancer
patients had poor outcomes.
Leukocytosis or leukopenia is a criteria for systemic
inflammatory response syndrome.28 Both leukocytosis and
leukopenia have a higher Acute Physiology and Chronic
Health Evaluation II (APACHE II) score. Previous studies of
CMV pneumonia in patients with lymphoma showed that
APACHE II score of more than 16 were poor prognostic
factors.24 Our study demonstrated that leukocytosis was
a predictable factor for worse outcome. This may be able to
explain the fact that patients with leukocytosis had higher
Table 4 Risk factors for mortality in patients with cytomegalovirus infection (nZ 107)
Variable Mortality, n (%) Univariate p Multivariate
Odds ratio (95% confidence
interval)
p
Demographic characteristics
Sex
Men (nZ 70) 40/70 (57.1) 0.760
Women (nZ 37) 20/37 (54.0)
Age (yr)
65 (nZ 58) 35/58 (60.3) 0.334
<65 (nZ 49) 25/49 (51.0)
Underlying malignancy
Solid organ malignancy
(nZ 75)
46/75 (61.3) 0.093
Hematological malignancy
(nZ 32)
14/32 (43.8)
Comorbid conditions
Heart failure (nZ 17) 12/17 (70.6) 0.195
Liver cirrhosis (nZ 4) 3/4 (75.0) 0.450
Chronic obstructive lung
disease (nZ 5)
3/5 (60.0) 0.856
Diabetes (nZ 33) 17/33 (51.5) 0.526
Rheumatological disease
(nZ 4)
1/4 (25.0) 0.235
Renal failure (nZ 5) 3/5 (60.0) 0.856
Predisposing factors
Receipt of chemotherapy
(nZ 62)
29/62 (46.8) 0.024 1.881 (0.630e5.617) 0.258
Yes (nZ 62) 29/62 (46.8) 0.023
No (nZ 45) 31/45 (68.9)
Use of corticosteroids
(nZ 27)
13/27 (48.1) 0.339
Mechanical ventilation
(nZ 35)
26/35 (74.3) 0.010 3.259 (1.012e10.489) 0.048
Coinfection (nZ 21) 11/21 (52.4) 0.740
Presentations
Leukocytosis (nZ 35) 27/35 (77.1) 0.003 6.855 (1.831e25.663) 0.004
Neutropenia (nZ 21) 10/21 (47.6) 0.386 1.489 (0.396e5.594) 0.556
Lymphopenia (nZ 90) 52/90 (57.8) 0.416 2.543 (0.533e12.139) 0.242
Hypoalbuminemia (nZ 60) 40/60 (66.7) 0.002 3.081 (1.451e18.095) 0.067
Treatment
Early appropriate treatment
No (nZ 77) 48/77 (62.3) 0.039 4.001 (1.398e11.448) 0.010
Yes (nZ 30) 12/30 (40.0)
446 Y.-C. Wang et al.APACHE II score and worse outcomes. Several studies had
demonstrated diverse relationship between the lympho-
penia and mortality.20,24 The differences between these
studies may result from diverse populations and variant
therapeutic regimens. Further studies are needed to
elucidate the relationship between lymphopenia and CMV-
associated fatality.
Severe sepsis is defined as patients with sepsis associ-
ated with dysfunction of organs distant from the site of
infection, including the respiratory failure.28 The esti-
mated mortality rate in patients with sepsis ranges from
20% to 50% and approaches 70% in those with multipleorgans failure.29 It is reasonable that acute respiratory
failure is a poor prognostic factor in infection. Several
studies demonstrated that CMV infection caused higher
mortality rate in patients with mechanical ventila-
tion.18,30,31 Our study also showed the mortality was higher
in patients with mechanical ventilation (74.3% vs. 47.2%;
pZ 0.008). Other studies had demonstrated the correla-
tions between the CMV infection and mechanical ventila-
tion.18,30,31 In immunocompetent patients with mechanical
ventilation, the incidence of CMV infection is raised.18,30,31
CMV infection itself may deteriorate the disease and
prolong mechanical ventilation and hospital stay.18,30,31
Cytomegalovirus viremia in cancer patients 447Both CMV infection and respiratory failure with mechanical
ventilation influenced each other and made it a more
challenge to the physicians.
Only 30 patients (28%) in our study who received appro-
priate antiviral agents for more than 3-day duration within
72 hours of infection diagnosis were considered to have
appropriate early treatment. Among them, 18 (60%) patients
survived under the antiviral treatment and the others 12
(40%) died. Seventy-seven patients (72%) did not receive
early antiviral treatment. Forty-eight of the 77 patients
died, accounting for a crude mortality rate of 62.3%. Ten
patients did not receive any antiviral agent throughout the
course of infection. Seven of them died before confirmation
of the diagnosis. Interestingly, the other three patients
survived for more than 1 month without any treatment. That
could be explained by the fact that CMV viremia did not
indicate the CMV disease. However, patients without
appropriate antiviral therapy had a higher mortality rate
than those with appropriate antiviral therapy (62.3% vs. 40%;
pZ 0.039). The result indicated that pre-emptive treatment
is recommended for better survival.
Several limitations of our study deserved to be acknowl-
edged. First, we observed substantial heterogeneity among
study populations. The risk factors in patients with solid
organ malignancies may differ from hematological malig-
nancies. Besides, there are a variety of malignancies in this
study. The prognosis in each kind of malignancy may differ
from each other. Second, the diverse stages of malignancy
may be associated with different outcomes. The nature
course of the disease is worse in late stage than early stage.
Third, the CMV viral load, which was not available in our
study, may be a significant variable in the outcome. Finally,
this is a retrospective study with limitations intrinsically.
In conclusion, the overall mortality rate of CMV viremia in
patients with malignancies was very high. On the basis of our
study, predictors of death associated with CMV viremia in
patients with malignancies included leukocytosis, mechan-
ical ventilation, and lack of appropriate early treatment.
Positive result of serum CMV PCR indicates high mortality
rate in cancer patients. Pre-emptive antiviral therapy is
recommended for better prognosis of these patients.Acknowledgment
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